NeoStem Announces UCSF Presentation of Phase 1 Results for T Regulatory Cell Immunotherapy for Type 1 Diabetes at American Diabetes Association Annual Meeting

NeoStem, Inc. (Nasdaq:NBS) a leader in the emerging cellular therapy industry, today announced the presentation of the results of an open-label dose escalation Phase 1 clinical study of autologous T regulatory cell (Treg) immunotherapy for type 1 diabetes mellitus (T1DM) indicating safety and tolerability following administration.
http://bit.ly/1ju9Xgl